Cytokinetics (CYTK) Q2 2024 Earnings
CYTK·Reported August 8, 2024·After market close
Cytokinetics reported Q2 2024 revenue of $249.0K, missed analyst consensus of $920.0K by $671.0K. Diluted EPS came in at $-1.31, missed the $-1.02 consensus by $0.29.
Revenue
$249.0Kmissed by $671.0K
Consensus: $920.0KDiluted EPS
$-1.31missed by $0.29
Consensus: $-1.02
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Cytokinetics's Q2 2024 earnings report.
Cytokinetics (CYTK) reported Q2 2024 earnings on August 8, 2024 after market close.
Cytokinetics reported revenue of $249.0K and diluted EPS of $-1.31 for Q2 2024.
Revenue missed the consensus estimate of $920.0K by $671.0K. EPS missed the consensus estimate of $-1.02 by $0.29.
You can read the 10-Q periodic report (0000950170-24-094743) directly on SEC EDGAR. The filing index links above go to sec.gov.